03:49 AM EDT, 09/08/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday results of a phase 3 study of Rybrevant plus Lazcluze as a potential treatment for certain patients with locally advanced or metastatic non-small cell lung cancer showed statistically significant and clinically meaningful overall survival improvement.

At a median follow-up of 37.8 months, the drug combination showed a "statistically significant" reduction in the risk of death compared with osimertinib, the company said.

Median overall survival for the combination is projected to exceed over four years compared with a median of three years with osimertinib, the company said.

The safety profile of the combination was consistent with an earlier analysis and no new safety signals were observed, Johnson & Johnson ( JNJ ) said.